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cal treatment of retroperitoneal lymph nodes in patients with
testicular cancer is made quite firmly including a comment
relating to combination chemotherapy that 'azoospermia
appears to persist for years if not permanently.' Elsewhere in
the volume however it is noted that 'Retrospective review of
a group of 28 patients indicated normal sperm counts in 46%
of patients after chemotherapy.' These differences of view
serve only to emphasise the problems which currently still
face the profession as does the statement in relation to
exenteration that, 'at the start of the operative procedure the
para-aortic nodes are palpated and any enlarged nodes
submitted for frozen section histology.' It is noted that
'metastatic disease in the para-aortic nodes is an absolute
contraindication to pelvic exenteration.' Nonetheless, 'formal
para-aortic lymphadenectomy is advised in the absence of
suspicious lymph nodes.' If the whole operation is pointless
in the presence of metastases it hardly seems necessary to do
the resection if metastases are absent. Perhaps this will be
clarified in a further edition.
There is a similar inconsistency in considering the follow
up of transitional cell tumours of the bladder where it is
noted that 'Among the 600 patients with transitional cell
carcinoma of the bladder, 4% developed upper tract lesions
after a delay of approximately 61 months.' The subsequent
advice is to have an annual radiological examination of the
upper tract for 2 years after initial diagnosis and treatment of
either an upper tract or bladder transitional cell carcinoma.
This seems inconsistent if most ofthe upper tract occurrences
in those treated for bladder carcinoma will occur subsequent
to 2 years.
It is always possible to find inconsistencies in any work of
reference and I have mentioned those which I have found,
merely to draw attention to the fact that I have read every
page of this book with interest and enjoyment. Each chapter
is well written and beautifully illustrated, whilst the sections
towards the end of the book dealing with the current know-
ledge concerning the possibilities for chemotherapy in each
group of tumours, the possible role of radiation therapy,
imaging techniques, tips on intestinal and vascular surgery
and observations upon medical evaluation, nutritional and
metabolic care, psychosexual support and care for the ter-
minally ill patient are thoughtful and most relevant additions
to a surgical text.
In my view, every department of urology should have two
copies of this book, one in its departmental library and the
other immediately available in the operating suite so that it
may be consulted at any time before or during an operation
for cancer of the urinary tract.
Philip H. Smith
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Our understanding of the relationship between immune
status and malignancy has a long and somewhat controver-
sial history. At one extreme of this controversy, immuno-
logical deficits are held to be intimately connected with
progression of malignant disease; others have dismissed any
immunological defects that may be found as post hoc pheno-
mena, a consequence of malignant disease rather than a
necessary precursor of it. The field is also complicated by the
range of (not easily reproducible) in vitro techniques that
have been used to define immunological defects and to probe
their mechanistic basis. To this one can add the basic
dilemma posed by insufficient knowledge of the in vivo role
both of the effector cell types being studied and their putative
regulatory mechanisms. For example, the regulation of
natural killer (NK) cell activity by monocytes begs the ques-
tions of whether NK cell activity is relevant to the develop-
ment of malignancy, and if it is, whether NK activity is
regulated by monocytes in vivo.
The authors are fully aware of these dilemmas, and they
seek to avoid them by providing a very comprehensive
assessment of the widest possible range of candidate regu-
latory and suppressive mechanisms that could influence the
growth of malignant tumours. Whilst this detailed scholar-
ship is an admirable summation of these possible mechan-
isms, in the process the major disadvantage of this book
quickly becomes apparent. The problem is that the majority
of the book appears to have been written in 1984-5, with a
few later additions in early 1987. In many fields, this delay
would not vitiate the endeavour, but immunology is develop-
ing rapidly, and particularly within the last 3-4 years when
several fundamental conceptual advances have occurred. The
most notable is probably the Bjorkman model for the struc-
ture of MHC antigens, with consequences for the nature ofT
cell recognition and the mechanisms of antigen processing,
transport and presentation. Another development that is now
more widely recognised is that of antigen processing by B
lymphocytes. The earlier explanation of cognate help which
involved antigen forming a bridge between receptors of T
and B cells is alluded to in the introduction to the chapter on
suppressor cells and human malignancy. The current view is
that the B cell receptor allows preferential uptake of native
antigen which is processed, followed by presentation of
associated T cell epitope(s) to CD4 T cells in the context of
the B cell's class II MHC.
As well as producing rapid developments in some areas,
immunologists also have a remarkable capacity to lose faith
(or at least lose interest) in others. As briefly discussed at the
end of the concluding chapter of the book, suppressor cells
are very much in the latter category. The current lack of
willingness on the part of some investigators to countenance
a major in vivo role for suppressor cells, whether or not as a
distinct functional population of cells, may subsequently
prove to be an extreme view, but it contrasts very strongly
with the zeitgeist so apparent in the earlier chapters of the
book.
One is left with the feeling that whilst the detailed discus-
sions of suppressor mechanisms developed in the book are
valid within their own terms of reference, time has moved on
too far and too fast for these considerations to have a major
impact on current thinking in this area, and necessarily limits
the value of the book even to a more general readership.
R.A. Robins
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The renaissance of interest in programmed cell death in
tumours, after a relatively low key burst of excitement in the
topic in the early 1970's, has been driven to a large degree by
the application of molecular biological techniques to this
fascinating topic. A review of the subject is therefore most
welcome. The Bowens' book has been expertly timed: it
precedes the publication of a Cold Spring Harbor publication
on programmed cell death by a few months. When CSH
publishes a monograph (after holding a meeting last Spring)
it suggests that programmed cell death has come of age!
How does a cell die? Bowen and Bowen give us plenty of
descriptions in their book: death by cell deletion, by necrosis,
apoptosis (programmed cell death), accidental cell death,
induced cell death, death by differentiation and death by
autolysis. Each of these definitions attempts to clarify the
loss of cells by natural or unnatural means, by suicide or by